Health Care [ 3/12 ] | Biotechnology [ 10/75 ]
NASDAQ | Common Stock
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.
Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus.
The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven.
Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 5, 26 | -1.91 Increased by +85.42% | -2.49 Increased by +23.21% |
| Nov 6, 25 | -3.04 Increased by +0.98% | -0.25 Decreased by -1.12 K% |
| Aug 6, 25 | -1.53 Decreased by -5.20 K% | -0.24 Decreased by -537.50% |
| May 5, 25 | -2.11 Decreased by -860.59% | -3.15 Increased by +32.98% |
| Mar 10, 25 | -13.10 Decreased by -5.85 K% | -3.67 Decreased by -256.95% |
| Nov 6, 24 | -3.07 Decreased by -648.78% | -2.16 Decreased by -42.13% |
| Aug 6, 24 | 0.03 Increased by +106.98% | -0.16 Increased by +118.75% |
| May 7, 24 | -0.22 Increased by +58.49% | -0.19 Decreased by -15.79% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 169.00 K Decreased by -73.13% | -19.88 M Increased by +75.80% | Decreased by -11.76 K% Increased by +9.93% |
| Sep 30, 25 | 741.00 K Decreased by -41.61% | -31.54 M Decreased by -63.75% | Decreased by -4.26 K% Decreased by -180.43% |
| Jun 30, 25 | 965.00 K Decreased by -9.05% | -15.86 M Decreased by -413.44% | Decreased by -1.64 K% Decreased by -444.62% |
| Mar 31, 25 | 311.00 K Decreased by -68.46% | 43.09 M Increased by +223.59% | Increased by +13.85 K% Increased by +491.84% |
| Dec 31, 24 | 629.00 K Decreased by -76.54% | -82.15 M Decreased by -194.53% | Decreased by -13.06 K% Decreased by -1.16 K% |
| Sep 30, 24 | 1.27 M Decreased by -60.82% | -19.26 M Decreased by -6.75% | Decreased by -1.52 K% Decreased by -172.47% |
| Jun 30, 24 | 1.06 M Decreased by -84.59% | 5.06 M Increased by +126.93% | Increased by +477.00% Increased by +274.80% |
| Mar 31, 24 | 986.00 K Decreased by -63.79% | -34.86 M Decreased by -51.88% | Decreased by -3.54 K% Decreased by -319.43% |